SI1644009T1 - COMPOSITION TO INCREASE TELECOMMUNICATION ACTIVITY AND TREATMENT OF HIV INFECTION - Google Patents
COMPOSITION TO INCREASE TELECOMMUNICATION ACTIVITY AND TREATMENT OF HIV INFECTION Download PDFInfo
- Publication number
- SI1644009T1 SI1644009T1 SI200432425T SI200432425T SI1644009T1 SI 1644009 T1 SI1644009 T1 SI 1644009T1 SI 200432425 T SI200432425 T SI 200432425T SI 200432425 T SI200432425 T SI 200432425T SI 1644009 T1 SI1644009 T1 SI 1644009T1
- Authority
- SI
- Slovenia
- Prior art keywords
- hiv infection
- compositions
- telomerase activity
- cycloastragenol
- cells
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 7
- 208000031886 HIV Infections Diseases 0.000 title claims abstract 5
- 208000037357 HIV infectious disease Diseases 0.000 title claims abstract 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title claims abstract 5
- 108010017842 Telomerase Proteins 0.000 title claims abstract 4
- 230000000694 effects Effects 0.000 title claims abstract 4
- 230000002708 enhancing effect Effects 0.000 claims abstract 2
- 238000009472 formulation Methods 0.000 claims abstract 2
- WENNXORDXYGDTP-UOUCMYEWSA-N cycloastragenol Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O)C4(C)C)[C@H]4[C@@H](O)C[C@H]3[C@]2(C)C[C@@H]1O WENNXORDXYGDTP-UOUCMYEWSA-N 0.000 claims 5
- WENNXORDXYGDTP-UHFFFAOYSA-N cyclosiversigenin Natural products O1C(C(C)(O)C)CCC1(C)C1C2(C)CCC34CC4(CCC(O)C4(C)C)C4C(O)CC3C2(C)CC1O WENNXORDXYGDTP-UHFFFAOYSA-N 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 claims 3
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 claims 3
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- KNESISUQBYQIIU-UHFFFAOYSA-N 6-Angeloyl-1,6-Dihydroxyfuranoeremophilan-9-one Natural products O1C(C(C)(O)C)CCC1(C)C1C2(C)CC=C3C4(C)CCC(O)C(C)(C)C4C(O)CC3C2(C)CC1O KNESISUQBYQIIU-UHFFFAOYSA-N 0.000 claims 1
- KZGXEJKMJNLRSF-UHFFFAOYSA-N Astragenol Natural products CC(C)(O)C1CCC(C)(O1)C2C(O)CC3(C)C4CC(O)C5(C)C(C)(C)C(O)CCC5(C)C4=CCC23C KZGXEJKMJNLRSF-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- 150000008505 β-D-glucopyranosides Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract 3
- 230000001154 acute effect Effects 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000002417 nutraceutical Substances 0.000 abstract 1
- 235000021436 nutraceutical agent Nutrition 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48098803P | 2003-06-23 | 2003-06-23 | |
| EP04777032.6A EP1644009B1 (en) | 2003-06-23 | 2004-06-23 | Compositions for increasing telomerase activity and treating hiv infection |
| PCT/US2004/020277 WO2005000245A2 (en) | 2003-06-23 | 2004-06-23 | Compositions and methods for increasing telomerase activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1644009T1 true SI1644009T1 (en) | 2018-04-30 |
Family
ID=33551962
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200432425T SI1644009T1 (en) | 2003-06-23 | 2004-06-23 | COMPOSITION TO INCREASE TELECOMMUNICATION ACTIVITY AND TREATMENT OF HIV INFECTION |
| SI200432463T SI2548880T1 (sl) | 2003-06-23 | 2004-06-23 | Sestavki za povečanje telomerazne aktivnosti |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200432463T SI2548880T1 (sl) | 2003-06-23 | 2004-06-23 | Sestavki za povečanje telomerazne aktivnosti |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7846904B2 (enExample) |
| EP (2) | EP2548880B1 (enExample) |
| JP (4) | JP5583882B2 (enExample) |
| KR (3) | KR20110089887A (enExample) |
| CN (1) | CN1809364B (enExample) |
| AP (1) | AP2280A (enExample) |
| AU (2) | AU2004251753C1 (enExample) |
| BR (1) | BRPI0411856A (enExample) |
| CA (1) | CA2528483C (enExample) |
| CY (2) | CY1119951T1 (enExample) |
| DK (2) | DK2548880T3 (enExample) |
| EA (1) | EA009442B1 (enExample) |
| ES (2) | ES2666864T3 (enExample) |
| HR (2) | HRP20180330T1 (enExample) |
| HU (2) | HUE036559T2 (enExample) |
| LT (2) | LT2548880T (enExample) |
| MX (1) | MXPA05013844A (enExample) |
| NZ (1) | NZ544191A (enExample) |
| PL (2) | PL2548880T3 (enExample) |
| PT (2) | PT2548880T (enExample) |
| SI (2) | SI1644009T1 (enExample) |
| TR (2) | TR201802543T4 (enExample) |
| WO (1) | WO2005000245A2 (enExample) |
| ZA (1) | ZA200509846B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
| US6337200B1 (en) | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
| NZ544191A (en) | 2003-06-23 | 2008-12-24 | Geron Corp | Compositions and methods for increasing telomerase activity |
| US9248088B2 (en) * | 2003-06-25 | 2016-02-02 | Telomerase Activation Sciences, Inc. | Compositions and methods for skin conditioning |
| EP1876893B1 (en) | 2005-04-15 | 2012-04-11 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| US8197860B2 (en) * | 2005-06-23 | 2012-06-12 | Nuliv Holding Inc. | Method for enhancing nutrient absorption with astragalosides |
| CN100333731C (zh) * | 2005-09-08 | 2007-08-29 | 南京医科大学 | 黄芪甲苷在制备治疗糖尿病周围神经病变药物中的应用 |
| CN100384830C (zh) * | 2006-01-12 | 2008-04-30 | 天津药物研究院 | 环黄芪醇类衍生物以及用途 |
| US7992749B2 (en) | 2006-03-30 | 2011-08-09 | Nike, Inc. | Support element for a carry strap |
| EP2101789B1 (en) | 2006-10-30 | 2014-12-31 | Geron Corporation | Combined telomerase inhibitor and gemcitabine for the treatment of cancer |
| EA201401193A1 (ru) * | 2007-06-04 | 2015-08-31 | Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити | Триарильные соединения и композиции, их содержащие |
| CN101225424B (zh) * | 2007-09-13 | 2013-05-29 | 天津药物研究院 | 环黄芪醇的单葡萄糖苷、其制备方法、药物组合物和应用 |
| US8168596B2 (en) * | 2008-10-17 | 2012-05-01 | Nuliv Holding Inc. | Use of cycloartane compounds for treating arthritis |
| HRP20161324T1 (hr) * | 2009-05-18 | 2016-11-18 | Telomerase Activation Sciences, Inc. | Pripravci i postupci za povećavanje telomerazne aktivnosti |
| WO2014186603A1 (en) * | 2013-05-15 | 2014-11-20 | Fybrands Corp. | Compositions for improving the hair, skin, and nails |
| CN106061940A (zh) | 2013-11-05 | 2016-10-26 | 本古里安大学内盖夫研究发展局 | 治疗糖尿病和由其引发的并发疾病的化合物 |
| CN104491185A (zh) * | 2014-12-06 | 2015-04-08 | 郭亮 | 一种祛风湿药酒及其制备方法 |
| CN104435371A (zh) * | 2014-12-06 | 2015-03-25 | 郭亮 | 一种用于治疗关节炎的药酒 |
| CN104435370A (zh) * | 2014-12-06 | 2015-03-25 | 王香平 | 风湿保健酒 |
| KR20160069857A (ko) | 2014-12-09 | 2016-06-17 | (주)스피어테크 | 텔로미어 활성을 증가시키기 위한 조성물 및 그 조성물의 제조방법 |
| CN104817610A (zh) * | 2015-03-15 | 2015-08-05 | 北京化工大学 | 利用硫酸水解制备环黄芪醇的方法 |
| AU2016243750B2 (en) | 2015-04-03 | 2022-02-03 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
| US10100285B2 (en) | 2015-04-03 | 2018-10-16 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
| CN106474094A (zh) * | 2015-08-31 | 2017-03-08 | 南京理工大学 | 一种环黄芪醇电纺纤维膜及其制备方法 |
| JP6869231B2 (ja) | 2015-09-11 | 2021-05-12 | プロパジェニクス インコーポレイテッド | ｅｘ ｖｉｖｏでの上皮細胞の増殖 |
| CN106307522A (zh) * | 2016-11-06 | 2017-01-11 | 谭淞文 | 一种抗衰老保健品及其制备方法和食用方法 |
| CN106831927B (zh) * | 2017-02-07 | 2018-02-09 | 江西师范大学 | 一种黄芪甲苷的合成方法 |
| CN108498521B (zh) * | 2017-02-24 | 2020-05-05 | 北京大学 | 环黄芪醇在制备抑制腹主动脉瘤的药物中的应用 |
| US10098922B1 (en) | 2017-11-30 | 2018-10-16 | Optigenex, Inc. | Increasing telomere length in a cell |
| WO2020028055A1 (en) * | 2018-07-31 | 2020-02-06 | ADLER, Benjamin, Aaron | Ophthalmic formulations and uses thereof |
| KR102655940B1 (ko) | 2018-08-13 | 2024-04-11 | (주)아모레퍼시픽 | 신규 진세노사이드, 및 이를 포함하는 항염 조성물 |
| US11000537B2 (en) | 2018-10-17 | 2021-05-11 | Amorepacific Corporation | Composition comprising novel ginsenoside |
| KR102635196B1 (ko) | 2018-10-17 | 2024-02-13 | (주)아모레퍼시픽 | 신규 진세노사이드를 포함하는 미백 조성물 |
| US11000538B2 (en) | 2018-10-31 | 2021-05-11 | Amorepacific Corporation | Composition for enhancing exercise ability or anti-fatigue comprising novel ginsenoside |
| WO2020131058A1 (en) * | 2018-12-20 | 2020-06-25 | Muhammed Majeed | Telomerase enhancement potential of ecdysterone |
| CN109942663B (zh) * | 2019-04-22 | 2021-10-26 | 中国人民解放军联勤保障部队第九八九医院 | 利用双相酸水解制备环黄芪醇的方法 |
| MX2019006749A (es) | 2019-06-10 | 2022-11-28 | Univ Mexico Nac Autonoma | Compuestos activadores de senescencia celular. |
| KR102842908B1 (ko) | 2019-09-27 | 2025-08-07 | (주)아모레퍼시픽 | 신규 진세노사이드를 포함하는 피부 탄력 개선용 조성물 |
| KR102842907B1 (ko) | 2019-09-27 | 2025-08-07 | (주)아모레퍼시픽 | 신규 진세노사이드를 포함하는 갱년기 증상의 예방 또는 개선용 조성물 |
| CN111419854B (zh) * | 2020-05-18 | 2021-03-30 | 南通大学 | 具有特殊七元环结构的三萜在制备预防和治疗神经损伤药物中的应用 |
| US12305233B1 (en) | 2020-07-09 | 2025-05-20 | Arizona Board Of Regents On Behalf Of Arizona | Ultra-high-throughput assay for telomerase repeat addition processivity |
| CN113480628B (zh) * | 2021-08-17 | 2022-06-21 | 贵州师范大学 | 一种贵州疣螈多肽tk-cath及其编码基因和应用 |
| CN113968894B (zh) * | 2021-11-05 | 2024-05-28 | 山西大学 | 一种用黄芪甲苷降解制备环黄芪醇的方法 |
| KR102666469B1 (ko) * | 2023-05-04 | 2024-05-17 | 주식회사 아리바이오 | 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물 |
| CN119818509B (zh) * | 2025-02-10 | 2025-10-17 | 山西中医药大学 | 黄芪醇在制备治疗或缓解帕金森病的产品中的应用 |
| CN120137936A (zh) * | 2025-03-14 | 2025-06-13 | 北京娅熙妍国际贸易有限公司 | 端粒酶变体及其在抗衰老中的应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6212792A (ja) * | 1986-07-18 | 1987-01-21 | Osaka Chem Lab | オウギサポニン類の単離法 |
| JPS6212791A (ja) * | 1986-07-18 | 1987-01-21 | Osaka Chem Lab | オウギサポニン、その単離法およびその用途 |
| IT1259645B (it) | 1992-04-10 | 1996-03-25 | Solis Srl | Metodo per la rivelazione della variazione di densita' di un tessuto e dispositivo per la sua attuazione |
| US6007989A (en) | 1992-05-13 | 1999-12-28 | Board Of Regents, The University Of Texas System | Methods of screening for compounds that derepress or increase telomerase activity |
| US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
| FR2695561B1 (fr) | 1992-09-17 | 1994-12-02 | Lvmh Rech Gie | Composition cosmétique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux. |
| US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
| JPH07238026A (ja) * | 1994-02-25 | 1995-09-12 | Pola Chem Ind Inc | 動脈硬化抑制剤及びこれを含む食品又は医薬 |
| AT402890B (de) | 1994-03-16 | 1997-09-25 | Berbi Gmbh | Verwendung von notoginsenosid r1 zur herstellung von arzneimitteln |
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| DK0778842T3 (da) * | 1994-07-07 | 2006-03-20 | Geron Corp | Mammal telomerase |
| US6162459A (en) | 1995-02-24 | 2000-12-19 | National Science Council | Acyclovir transdermal delivery system |
| AUPN411195A0 (en) | 1995-07-10 | 1995-08-03 | Cathay Herbal Laboratories Pty Ltd | Medicinal composition |
| CN1079265C (zh) | 1995-08-01 | 2002-02-20 | 裴国增 | 灵芝口服液及其配制方法 |
| US5785977A (en) | 1996-02-07 | 1998-07-28 | Breithbarth; Richard | Non-metallic microparticle carrier materials |
| US5916565A (en) | 1996-03-08 | 1999-06-29 | In Clover, Inc. | Product and method for treating joint disorders in vertebrates |
| TW452494B (en) | 1996-03-12 | 2001-09-01 | Jang De Shan | Herbal composition for stimulating blood circulation |
| US5900226A (en) | 1997-04-09 | 1999-05-04 | Uop Llc | Drying agents for non-foamed polyurethanes |
| JPH1036388A (ja) * | 1996-07-25 | 1998-02-10 | Kureha Chem Ind Co Ltd | ジンセノサイド類含有ｈｓｐ４７合成抑制剤 |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| NZ334709A (en) | 1996-10-01 | 2001-06-29 | Univ Technology Corp | Detection of hTRT activity or expression and use in the treatment of cancer |
| US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
| NZ336869A (en) | 1997-01-28 | 2001-01-26 | Graeme A Close | Pharmaceutical compositions comprising aqueous alcoholic Centipeda plant extracts |
| US5786343A (en) | 1997-03-05 | 1998-07-28 | Immudyne, Inc. | Phagocytosis activator compositions and their use |
| BR9811758A (pt) | 1997-09-05 | 2000-08-29 | Procter & Gamble | Produto de limpeza e condicionamento para tratamento pessoal de utilização única, descartável e processos para manufaturar, para distribuir e para limpar e condicionar a pele com esse produto |
| ES2186199T3 (es) | 1997-09-12 | 2003-05-01 | Procter & Gamble | Articulo de limpieza y acondicionador para la piel o el pelo. |
| JP2002500040A (ja) | 1998-01-12 | 2002-01-08 | コールド スプリング ハーバー ラボラトリー | 細胞の寿命の延長、方法および試薬 |
| GB9815177D0 (en) | 1998-07-13 | 1998-09-09 | King S College London | Treatment of skin disorders |
| WO2000008135A1 (en) | 1998-08-09 | 2000-02-17 | Board Of Regents, The University Of Texas System | Methods and compositions for inhibiting or stimulating telomerase assembly |
| CA2352486A1 (en) | 1998-11-25 | 2000-06-02 | Genetica, Inc. | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
| JP2000204091A (ja) * | 1999-01-13 | 2000-07-25 | Nippon Suisan Kaisha Ltd | 新規ベンゾジオキソ―ル誘導体 |
| JP2000229827A (ja) * | 1999-02-05 | 2000-08-22 | Kose Corp | 皮膚外用剤 |
| JP2000229834A (ja) * | 1999-02-10 | 2000-08-22 | Kanebo Ltd | 化粧料 |
| AUPQ127399A0 (en) * | 1999-06-29 | 1999-07-22 | Guangzhou University Of Traditional Chinese Medicine | Compositions and methods for treating or preventing osteoporosis |
| KR100858465B1 (ko) | 1999-09-10 | 2008-09-16 | 제론 코포레이션 | 올리고뉴클레오티드 엔3'→피5' 티오포스포라미데이트,이의 합성 및 용도 |
| JP2001258505A (ja) * | 2000-03-24 | 2001-09-25 | Fancl Corp | 食品組成物 |
| CA2307393A1 (en) * | 2000-05-01 | 2001-11-01 | The University Of British Columbia | Ginsenoside chemotherapy |
| US6277396B1 (en) | 2000-05-11 | 2001-08-21 | Maximum Human Performance, Inc. | Dietary supplement containing a thermogenic substance and an adrenal support substance |
| EP1295893A4 (en) | 2000-05-31 | 2005-10-26 | Japan Science & Tech Agency | REGENERATION PROMOTERS OF CUTANE TISSUE CONTAINING GINSENOSIDE RB1 |
| CN1172677C (zh) * | 2000-07-14 | 2004-10-27 | 复旦大学附属中山医院 | 黄芪甲苷在制备药物组合物中的应用 |
| GB0105613D0 (en) | 2001-03-07 | 2001-04-25 | Univ Cambridge Tech | Pharmaceutically effective compounds and their use |
| WO2002007732A2 (en) | 2000-07-26 | 2002-01-31 | Cambridge University Technical Services Limited | Use of panaxatriol for stimulation angiogenesis |
| US6696094B2 (en) | 2000-10-18 | 2004-02-24 | Tzu-Sheng Wu | Herbal pharmaceutical composition for treatment of HIV/AIDS patients |
| CN1242807C (zh) * | 2000-11-08 | 2006-02-22 | 天津市延龄营养保健品有限公司 | 一种抗皮肤过敏的药物组合物及其制法和用途 |
| CN1369276A (zh) * | 2001-02-12 | 2002-09-18 | 徐秀荣 | 有效减轻体重的组合物和方法 |
| JP2002275086A (ja) * | 2001-03-15 | 2002-09-25 | Fancl Corp | 虚弱体質改善用組成物 |
| WO2002091999A2 (en) | 2001-05-09 | 2002-11-21 | Geron Corporation | Treatment for wounds |
| US20020182272A1 (en) | 2001-05-30 | 2002-12-05 | Bruce Halstead | Methods of treatment of HIV-associated conditions |
| JP2003089687A (ja) * | 2001-07-03 | 2003-03-28 | Tanabe Seiyaku Co Ltd | 新規ブタジエン誘導体、その製法およびその合成中間体 |
| US20040180938A1 (en) | 2001-07-03 | 2004-09-16 | Akio Ohtani | Novel butadiene derivatives, process for preparation of the same and intermediates for the synthesis thereof |
| US6855344B2 (en) | 2001-07-17 | 2005-02-15 | Integrated Chinese Medicine Holdings, Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| US20030108629A1 (en) | 2001-07-17 | 2003-06-12 | Chou Wen Hsien | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| CN1164608C (zh) * | 2001-08-31 | 2004-09-01 | 上海中医药大学 | 具有抗心肌纤维化作用的黄芪皂甙甲 |
| CN1406585A (zh) | 2001-09-07 | 2003-04-02 | 中国科学院上海药物研究所 | 一种治疗病毒性心肌炎的药物组合物 |
| JP2003160497A (ja) * | 2001-11-22 | 2003-06-03 | Toshin Kagaku Kk | 皮膚外用剤 |
| US20070042962A1 (en) | 2002-02-04 | 2007-02-22 | Adams David S | Peptide dependent upregulation of telomerase expression |
| CN1236803C (zh) | 2002-03-20 | 2006-01-18 | 郑国芃 | 一种治疗风湿症的中药 |
| CN1189176C (zh) * | 2002-07-22 | 2005-02-16 | 江苏正大天晴药业股份有限公司 | 黄芪甲甙组合物及其制备方法 |
| AU2003228378A1 (en) * | 2003-03-26 | 2004-11-23 | Westlake Partners | Herbal compositions and methods for effecting weight loss in humans |
| US20070259014A1 (en) * | 2003-06-20 | 2007-11-08 | Vgx Pharmaceuticals, Inc. | Compositions for and Methods for Treating Hiv |
| NZ544191A (en) * | 2003-06-23 | 2008-12-24 | Geron Corp | Compositions and methods for increasing telomerase activity |
| US9248088B2 (en) | 2003-06-25 | 2016-02-02 | Telomerase Activation Sciences, Inc. | Compositions and methods for skin conditioning |
| US20070122501A1 (en) | 2003-06-27 | 2007-05-31 | Hong Kong University Of Science And Technology | Formulations containing astragalus extracts and uses thereof |
-
2004
- 2004-06-23 NZ NZ544191A patent/NZ544191A/en not_active IP Right Cessation
- 2004-06-23 HU HUE04777032A patent/HUE036559T2/hu unknown
- 2004-06-23 LT LTEP12180710.1T patent/LT2548880T/lt unknown
- 2004-06-23 KR KR1020117017367A patent/KR20110089887A/ko not_active Ceased
- 2004-06-23 PL PL12180710T patent/PL2548880T3/pl unknown
- 2004-06-23 DK DK12180710.1T patent/DK2548880T3/en active
- 2004-06-23 KR KR1020137031630A patent/KR101465515B1/ko not_active Expired - Lifetime
- 2004-06-23 JP JP2006517617A patent/JP5583882B2/ja not_active Expired - Lifetime
- 2004-06-23 EP EP12180710.1A patent/EP2548880B1/en not_active Expired - Lifetime
- 2004-06-23 EP EP04777032.6A patent/EP1644009B1/en not_active Expired - Lifetime
- 2004-06-23 KR KR1020057024720A patent/KR101312389B1/ko not_active Expired - Lifetime
- 2004-06-23 ZA ZA200509846A patent/ZA200509846B/en unknown
- 2004-06-23 ES ES04777032.6T patent/ES2666864T3/es not_active Expired - Lifetime
- 2004-06-23 SI SI200432425T patent/SI1644009T1/en unknown
- 2004-06-23 HR HRP20180330TT patent/HRP20180330T1/hr unknown
- 2004-06-23 PT PT12180710T patent/PT2548880T/pt unknown
- 2004-06-23 CN CN2004800172464A patent/CN1809364B/zh not_active Expired - Lifetime
- 2004-06-23 PT PT47770326T patent/PT1644009T/pt unknown
- 2004-06-23 WO PCT/US2004/020277 patent/WO2005000245A2/en not_active Ceased
- 2004-06-23 DK DK04777032.6T patent/DK1644009T3/en active
- 2004-06-23 US US10/562,374 patent/US7846904B2/en active Active
- 2004-06-23 EA EA200600076A patent/EA009442B1/ru unknown
- 2004-06-23 AU AU2004251753A patent/AU2004251753C1/en not_active Ceased
- 2004-06-23 LT LTEP04777032.6T patent/LT1644009T/lt unknown
- 2004-06-23 TR TR2018/02543T patent/TR201802543T4/tr unknown
- 2004-06-23 ES ES12180710T patent/ES2716528T3/es not_active Expired - Lifetime
- 2004-06-23 SI SI200432463T patent/SI2548880T1/sl unknown
- 2004-06-23 TR TR2019/03587T patent/TR201903587T4/tr unknown
- 2004-06-23 PL PL04777032T patent/PL1644009T3/pl unknown
- 2004-06-23 HU HUE12180710A patent/HUE043168T2/hu unknown
- 2004-06-23 CA CA2528483A patent/CA2528483C/en not_active Expired - Lifetime
- 2004-06-23 MX MXPA05013844A patent/MXPA05013844A/es active IP Right Grant
- 2004-06-23 AP AP2005003474A patent/AP2280A/xx active
- 2004-06-23 BR BRPI0411856-1A patent/BRPI0411856A/pt not_active Application Discontinuation
-
2008
- 2008-11-25 AU AU2008249200A patent/AU2008249200A1/en not_active Abandoned
-
2010
- 2010-03-05 US US12/718,812 patent/US8759304B2/en not_active Expired - Lifetime
-
2011
- 2011-02-21 JP JP2011035191A patent/JP5841337B2/ja not_active Expired - Lifetime
-
2013
- 2013-10-23 JP JP2013219989A patent/JP5913253B2/ja not_active Expired - Fee Related
-
2014
- 2014-06-24 US US14/313,698 patent/US20150093455A1/en not_active Abandoned
-
2016
- 2016-01-04 JP JP2016000130A patent/JP2016041770A/ja not_active Withdrawn
-
2018
- 2018-02-26 CY CY20181100225T patent/CY1119951T1/el unknown
-
2019
- 2019-02-18 HR HRP20190322TT patent/HRP20190322T1/hr unknown
- 2019-03-22 CY CY20191100342T patent/CY1121447T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1644009T1 (en) | COMPOSITION TO INCREASE TELECOMMUNICATION ACTIVITY AND TREATMENT OF HIV INFECTION | |
| BR0314236A (pt) | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos | |
| DOP2008000001A (es) | Oxazolidinonas substituidas y su uso | |
| WO2005044179A8 (en) | Formulations containing astragalus extracts and uses thereof | |
| BR0316050A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
| CA2396186A1 (en) | Agents for the treatment of skin disorders | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| SG146691A1 (en) | Methods of preparing and using stem cell compositions and kits comprising the same | |
| Galabueva et al. | Optimization of modern methods of treating chronic generalized periodontitis of mild severity | |
| JP2006512419A5 (enExample) | ||
| BRPI0414428A (pt) | composições farmacêuticas | |
| DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
| BR9909474A (pt) | Formas ii, cristalina e v de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, solvato de etanol de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, composição, composto, uso de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, e, processos para o tratamento de uma infecção viral em um humano e para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol | |
| BRPI0409884A (pt) | compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BRPI0409818A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| MX2023010827A (es) | Derivados de pirazolopiridina y sus usos. | |
| US10413586B2 (en) | Antiviral agent comprising recombinant mistletoe lectins | |
| RS102304A (sr) | Preparati za terapeutsku primenu koji sadrže vitamin, so metala i insulin ili hormon rasta | |
| ATE418540T1 (de) | Galloylpeptide | |
| BRPI0412453A (pt) | uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo | |
| TW200505916A (en) | 7-azaindoles and the use thereof as therapeutic agents | |
| WO2005123651A8 (fr) | L-2-(a-hydroxypentyle)benzoates, leur elaboration et leur utilisation | |
| TW200740440A (en) | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | |
| JP6853547B2 (ja) | コラーゲン分解阻害用組成物 |